Leerink Partners Remains Bullish on Merck & Co. (MRK)

Group 1 - Merck & Co., Inc. (NYSE:MRK) is considered a strong investment opportunity, particularly for beginners, with a Buy rating maintained by analyst Daina Graybosch from Leerink Partners [1][2] - The positive outlook is attributed to Merck's strategic position in the antibody-drug conjugates (ADCs) market, specifically for treating extensive-stage small cell lung cancer (ES-SCLC) [2][3] - Merck's I-DXd has a significant first-to-market advantage, supported by a larger and more diverse patient population in its studies, which may facilitate accelerated approval [3] Group 2 - Merck operates in two main segments: Pharmaceuticals, which includes vaccines and human health products, and Animal Health, which focuses on veterinary vaccines and pharmaceuticals [4]